<DOC>
	<DOCNO>NCT00630760</DOCNO>
	<brief_summary>This phase I study determine safety profile NRX 194204 schedule ; evaluate pharmacokinetic profile NRX 194204 cancer patient ; investigate anti-tumor activity manifest standard response criterion , tumor marker .</brief_summary>
	<brief_title>Oral NRX 194204 Patients With Refractory Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Signed date informed consent . Histologically confirm cancer refractory conventional therapy refractory cancer know effective standard therapy . Measurable nonmeasurable disease . Male female , 18 75 year age , inclusive . ECOG Performance Status 02 Life expectancy great 24 week . Able swallow oral capsule form drug . Hematology : Hemoglobin great equal 8.5 ; Platelets great equal to100,000 ; Neutrophils great equal 1500 PT PTT within normal limit , except patient receive oral Vitamin K antagonist thromboembolic prophylaxis , INR le 2 allowable . Biochemistry : Total bilirubin less equal 1.5 x ULN ; AST/ALT le equal 3.0 x ULN ; Serum creatinine less equal 2.0 mg/dl ; Serum calcium less equal 11.5 mg/dl ; Fasting serum triglyceride less equal 2.5 x ULN Endocrine : Thyroid stimulate hormone ( TSH ) within institutional normal limit ( typically great 0.5 mU/L less 5.5 mU/L ) Negative urine pregnancy test woman childbearing potential screening Day 0 , agreement use two reliable form contraception therapy 1 month follow discontinuation therapy unless abstinence choose birth control method . Able follow study instruction , accessible treatment followup , likely complete study requirement Major surgery within previous 4 week ; large field radiation therapy chemotherapy , include investigational agent participation another clinical study within previous 3 week ; mitomycin C nitrosoureas within 6 week . In instances patient must fully recover acute toxicity relate prior therapy . Systemic retinoid therapy , large dos Vitamin A previous 4 week . Patients prior current history thyroid disease , history pituitary disease , history prior current treatment thyroid replacement hormone . Primary brain tumor , active brain metastasis include progression last scan evidence cerebral edema , clinical symptom brain metastasis . Patients prior history brain metastasis must brain imaging perform find stable improve minimum interval 8 week . Requirement steroid . Note : Patients take stable dosage GnRH analogue Megace least previous 3 month allow study . Current enrollment investigational drug device study participation study within 21 day entry study . Prior enrollment study ( Quest 19420410100 ) ; patient may enroll treat one dose level . Known sensitivity ingredient study medication . Known HIVpositive patient . Females pregnant , nursing , plan pregnancy . History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study medication . Clinically significant abnormality screen ECG ( QTc great 480 msec ) . Patient condition situation , investigator 's opinion , may put him/her significant risk , may confound study result , may interfere significantly his/her participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>